The cancer, originally results from genome mutation which cause celllar dysfunction and uncontrolled cell growth.  The cancers type depend on location and their mutation sequence of message RNA.  We design and synthesize a variety of small interfering RNA (siRNA) in terms of offending genetic characteristics.  In these cases, we use a non-viral vectors to deliver the tumor suppressors (siRNA, etc) to cancer cells.  Consequently, siRNA results in degradation of mutated genome, and thus halt translation of the offending message into protein form and suppress growth of tumor cells.  The clinical trials show that our therapies can be used along or in combination with conventional treatment such as surgery, radiation therapy, chemotherapy and monoclonal antibodies.
 
Core technologies:
 
    ·  Nanomaterials,  Polymer and liposome vectors
 
   ·  Targed compound of solid tumors
 
   ·  Encapsulation of siRNA inside the vector 
 
   ·  Gensome transduction
OUR TECHNOLOGIES
NABI
GENMED